Acasti Pharma Inc. (NASDAQ:ACST) Short Interest Update

Acasti Pharma Inc. (NASDAQ:ACST) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 3,800 shares, an increase of 171.4% from the March 31st total of 1,400 shares. Approximately 0.1% of the shares of the company are sold short. Based on an average trading volume of 25,600 shares, the short-interest ratio is presently 0.1 days.

Analyst Ratings Changes

Separately, Craig Hallum initiated coverage on shares of Acasti Pharma in a research report on Wednesday, February 7th. They issued a “buy” rating and a $6.00 price target for the company.

Acasti Pharma Price Performance

Shares of ACST opened at $2.90 on Friday. The firm has a fifty day moving average price of $3.32 and a 200 day moving average price of $2.74. Acasti Pharma has a 1-year low of $1.72 and a 1-year high of $3.84. The stock has a market cap of $27.26 million, a PE ratio of -0.57 and a beta of 1.49.

Acasti Pharma (NASDAQ:ACST) last announced its earnings results on Monday, February 12th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. As a group, equities analysts expect that Acasti Pharma will post -1.44 EPS for the current fiscal year.

About Acasti Pharma

Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.